ZEALAND PHARMA/S (NASDAQ:ZEAL) has been given a consensus rating of “Buy” by the six brokerages that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $24.00.
Several equities analysts have recently weighed in on the company. Goldman Sachs Group cut ZEALAND PHARMA/S from a “buy” rating to a “neutral” rating in a report on Monday, December 17th. Needham & Company LLC raised their price objective on ZEALAND PHARMA/S from $26.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 19th. ValuEngine cut ZEALAND PHARMA/S from a “hold” rating to a “sell” rating in a report on Friday, November 16th. restated a “positive” rating on shares of ZEALAND PHARMA/S in a report on Thursday, September 27th. Finally, Zacks Investment Research upgraded ZEALAND PHARMA/S from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Tuesday, January 1st.
Shares of ZEALAND PHARMA/S stock opened at $14.25 on Friday. The firm has a market cap of $435.65 million, a P/E ratio of -9.63 and a beta of 1.90. ZEALAND PHARMA/S has a 12 month low of $11.51 and a 12 month high of $18.91.
ZEALAND PHARMA/S (NASDAQ:ZEAL) last released its quarterly earnings results on Thursday, November 15th. The company reported $4.69 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $5.20. ZEALAND PHARMA/S had a positive return on equity of 91.98% and a negative net margin of 483.00%. Analysts expect that ZEALAND PHARMA/S will post -2.47 earnings per share for the current fiscal year.
ZEALAND PHARMA/S Company Profile
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.
See Also: Moving Average (MA)
Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.